PHARMACEUTICAL IP

  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Insights
    • Articles
    • Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Insights
    • Articles
    • Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional in-house
  • Sectors
  • Articles
  • Our team
  • Join us
  • Our offering
  • Fractional in-house
  • Sectors
  • Articles
  • Our team
  • Join us

Artificial intelligence is not breaking patent law: EPO publishes DABUS decision (J 8/20)

  • Sector: AI drug discovery
  • 16th August 2022
 

The EPO Board of Appeal has published its full decision on the question of whether a machine can be an inventor (J 8/20). The Board of Appeal had previously announced its decision to refuse two European patent applications naming an algorithm (“DABUS”) as the sole inventor at the end of last year.

The decision in J 8/20 demonstrates that the current patent system is more than capable of dealing with AI inventions when and if they arise, without harming innovation or treating the AI inventors unfairly. Thus, contrary to the recent Nature article on this topic, AI is not breaking patent law. 

Case Background

J 8/20 relates to appeals of the decisions to refuse two European patent applications (EP3564144 and EP3563896) for failing to designate a natural person as an inventor. The patent applications purportedly relate to the inventions of an AI (“DABUS”). Whilst the AI was specified as the inventor, the patent applicant (and self identified owner of the inventions) was Dr Thaler. 

Succession of title

One of the fundamental issues with AI inventors is establishing the chain of title from the invention to the applicant for the invention from an inventor (the AI) lacking legal personality. Whilst DABUS is said to be capable of inventing, it does not yet seem capable of applying and owning a patent for its invention. This responsibility has been taken on by the inventor of DABUS, Dr Thaler. Dr Thaler argued that he derived the right to DABUS’s inventions by virtue of being the AI’s employer. 

The EPO Receiving Section rejected the applications on the ground that the applicant’s right to the invention had not been established. Particularly, DABUS lacks legal personality and so cannot transfer rights to the inventions to Dr Thaler (Article 60(1) EPC and Article 81 EPC). The Board of Appeal agreed with this assessment, noting that “under the EPC the designated inventor has to be a person with legal capacity. This is not merely an assumption on which the EPC was drafted. It is the ordinary meaning of the term inventor”. 

Innovation and fairness

A central tenet of the AI inventor team’s argument is that denying applicants the right to name an AI as an inventor will stifle innovation. However, this argument ignores the simple workaround that, under European patent law, the user or the owner of a device involved in an inventive activity can just designate themselves as inventor (r. 4.6.6). 

The Board of Appeal in the case in question also rejected the applicants argument that the public has a right to know who the inventor is and how the invention was made. The Board of Appeal noted that an inventor has the right for their name to be withheld from publication, and that a third party has no rights in this respect (r. 4.3.6). 

The Board of Appeal concluded that they were convinced that there is not a  problem of unequal treatment for computer assisted inventions calling for an evolutive interpretation of European patent law. The Board of Appeal particularly was not aware of any case law which would prevent the user or the owner of a device involved in an inventive activity to designate himself as the inventor under European patent law. 

If an applicant wished to acknowledge the AI inventor out of fairness, they are free to do this in the description (r. 4.3.7). If DABUS is an inventor, the real question of fairness is therefore how Dr Thaler is planning to compensate DABUS in exchange for Dr Thaler’s exploitation of DABUS’s inventions absent an employment contract between Dr Thaler and DABUS, that DABUS freely entered into. 

Final thoughts

While philosophical discussions of AI inventorship may soon become pertinent as the field develops, the Board of Appeal in J 8/20 found no legal, moral or practical difficulties with dealing with such inventions under the current system. 

As a final observation, it is a shame that the present debate over AI inventorship is based on questionable science. Dr Thaler claims that his algorithms are not just capable of inventing, but that they are also capable of sentience and near-death experiences. As long ago as 1996, Dr Thaler also claimed that his algorithms provide credible evidence for a “virtual afterlife”, and the religious concepts of salvation and damnation. The Board in J 8/20 stressed that the appeal did not relate to whether an AI, or DABUS in particular, is capable of inventing. Unlike the courts and patent offices, however, the willingness of the patent community to take Dr Thaler and his “imagination engines” seriously is rather embarrassing.

This post is based on a previous article on IPKat.

Related insights...

Are AI-discovered drug patents blocking innovation? A response to the Science article

  • 25th June 2025
Are AI-discovered drug patents truly blocking innovation, or does a new Science article on the topic misunderstand on how pharma IP strategy?

IP implications of the FDA guidance for use of AI in drug development

  • 17th June 2025
Learn how the FDA’s new draft guidance on the use of AI in drug development may impact the industry.

Is it time for patent offices to enter the bioinformatic age?

  • 13th June 2025
In a world in which incalculable amounts of sophisticated sequence data is freely available, are the clunky processes necessary to input patent sequence data really fit-for-purpose?

An LLM is not (yet) a person skilled in the art (T 1193/23)

  • 20th May 2025
The EPO clarifies that an LLM interpretation of a technical term in a patent is not yet evidence of how a skilled person would interpret the term.

OpenAI’s large language model (LLM) patents

  • 29th April 2025
For tech innovators seeking to understand evolving intellectual property strategies, OpenAI’s recent pivot offers essential guidance: far from relying solely on trade secrets, the AI leader is now aggressively pursuing and accelerating patent grants, signaling a significant shift.

AlphaFold: From Nobel Prize to drug-discovery gold mine?

  • 29th April 2025
AlphaFold, a machine learning model for predicting protein structure, is arguably one of the greatest achievements of AI so far. Whilst large language models such as ChatGPT can write poems and make pretty pictures, AlphaFold has the potential to dramatically impact the life-and-death world of drug discovery. AlphaFold represents truly ground-breaking science for which its…

IP strategy for AI-assisted drug discovery

  • 29th April 2025
AI has been hailed as a potentially revolutionary tool for accelerating and enhancing the difficult and expensive process of drug discovery. Medicine perhaps represents the field in which AI has the most to offer humanity. However, the nascent field of AI-assisted drug design also highlights the need for IP strategy to be as forward-looking and…

G 2/21 applied to software inventions (T 0687/22)

  • 29th April 2025
The EPO Board of Appeal decision in T 0687/22 confirms beyond doubt the relevance of G 2/21 to software inventions. The decision in T 0687/22 links the case law from G 1/19 and G 2/21 to highlight the importance of establishing a credible technical effect of software invention. The Patentee in the case made several attempts to formulate an objective technical problem solved by the invention based…

Too broad, too early? AI platform for cell analysis found to lack technical character and sufficiency (T 0660/22, Cell analysis/NIKON)

  • 29th April 2025
This decision highlights some of the challenges associated with trying to broadly protect software-based platform technology for biological research.

Insilico Medicine: Lessons in IP strategy from a front-runner in AI-drug discovery

  • 5th February 2025
The intersection of AI and pharmaceutical development presents unprecedented opportunities but also raises complex legal questions. Recent developments and successes in AI-drug discovery highlight some of the key IP issues in AI-drug development. Companies are being forced to tackle these issues head-on as the IP law advances almost as quickly as the science. In a previous…
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2025 All Rights Reserved

Keep in touch

Subscribe

Contact Us